Subcutaneous Immunoglobulin (SCIg): What Patients Need to Know About Self-Administered Ig Therapy

For years, patients who needed immunoglobulin therapy had one option: sit in a chair for several hours while antibodies dripped into a vein. That is no longer the only path. Subcutaneous immunoglobulin — known as SCIg — delivers the same life-sustaining antibodies through a small needle just under the skin, often at home, on your own schedule. It is giving thousands of patients something that chronic illness often takes away: the ability to plan their weeks around their lives instead of their infusions.

What Is Subcutaneous Immunoglobulin?

Subcutaneous immunoglobulin is a concentrated solution of human antibodies (immunoglobulin G, or IgG) that is infused into the fatty tissue just beneath the skin. Like its intravenous counterpart IVIG, SCIg is derived from pooled plasma donated by thousands of healthy donors. The antibodies help protect patients whose immune systems cannot produce enough on their own.

The conditions treated with SCIg are the same as those treated with IVIG, most commonly:

• Primary immunodeficiency disorders (PI) — genetic conditions where the body cannot make adequate antibodies
• Chronic inflammatory demyelinating polyneuropathy (CIDP) — an autoimmune condition affecting the peripheral nerves
• Secondary immunodeficiency — immune deficiency caused by certain cancers or immunosuppressive treatments

The fundamental difference is the delivery route. Rather than entering a vein directly, the immunoglobulin is slowly absorbed through subcutaneous tissue. This slower absorption creates a more gradual rise in IgG blood levels — and that distinction turns out to have meaningful clinical consequences that benefit many patients.

SCIg vs. IVIG: Key Differences

If both therapies deliver the same antibodies, why does the route matter? Because how a medication enters the body shapes everything from side effects to scheduling to how patients feel day to day.

The steadier IgG levels achieved with SCIg deserve special attention. With IVIG, antibody levels spike right after infusion and then slowly decline over the next three to four weeks. Many patients report feeling great in the days after an IVIG infusion but increasingly fatigued or unwell as levels drop before the next dose — a phenomenon patients call the “wear-off effect.” SCIg’s more frequent, smaller doses keep IgG levels in a narrower range, which often eliminates this roller-coaster pattern entirely.

The Two Main SCIg Products: Hizentra and Hyqvia

In the United States, two SCIg products dominate the market. They work differently, and understanding those differences helps patients and physicians choose the right fit.

Hizentra (Immune Globulin Subcutaneous, 20%)

Hizentra is a 20% concentrated immunoglobulin solution administered through a small portable pump. It is typically infused weekly, though some patients use it biweekly or even daily with a manual push method (using a syringe rather than a pump). Because it does not include a spreading agent, the volume that can be infused at each site is limited — which means patients often use two to four needle sites simultaneously.

Hyqvia (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase)

Hyqvia takes a different approach. It pairs a 10% immunoglobulin solution with hyaluronidase, an enzyme that temporarily loosens subcutaneous tissue so that larger volumes of fluid can be absorbed at a single site. This allows monthly dosing — the same frequency as IVIG — with just one or two needle sites. The trade-off is a longer infusion time per session and a two-step process (the enzyme is infused first, then the immunoglobulin).

A practical detail that often goes unmentioned: patients with very high immunoglobulin dose requirements may find that Hizentra’s weekly schedule with multiple sites becomes cumbersome at high volumes. Hyqvia’s ability to deliver larger volumes at a single site can be a significant quality-of-life advantage for these patients. On the other hand, patients who are sensitive to hyaluronidase or who prefer the steadiest possible IgG levels tend to do better with Hizentra. For a broader comparison of immunoglobulin products, see the IVIG brands comparison guide.

How Self-Administration Works

The idea of infusing medication into your own body can sound intimidating. But here is the truth: most patients master SCIg self-infusion within two to four training sessions, and many describe it as far simpler than they expected.

The process follows a consistent routine:

1. Gather supplies — Remove the immunoglobulin vials from the refrigerator about 20–30 minutes early to allow them to reach room temperature (cold solution is more uncomfortable). Lay out the pump, tubing, subcutaneous needles, alcohol swabs, gauze, and a sharps container.
2. Prepare the medication — Draw the immunoglobulin into syringes and attach them to the pump tubing. For Hyqvia, a separate syringe of hyaluronidase is prepared as well.
3. Choose and clean infusion sites — Common sites include the abdomen, thighs, upper arms, and hips. Clean each site with an alcohol swab and let it dry.
4. Insert needles — Small subcutaneous needles (typically 24–27 gauge — quite thin) are inserted at a shallow angle into the fatty tissue. Many patients barely feel the insertion, especially after the first few times.
5. Start the pump — Program the infusion rate and press start. The pump quietly pushes the medication through the tubing and into the subcutaneous tissue.
6. Monitor and wait — During the infusion, patients can watch television, work, read, or handle household tasks. Movement is somewhat limited by the tubing, but most people find comfortable ways to go about their routine.
7. Disconnect and document — When the infusion is complete, remove the needles, apply light pressure with gauze, dispose of sharps safely, and log the infusion details.

The Pump and Infusion Sites

The subcutaneous immunoglobulin pump is a small, portable, battery-powered device — roughly the size of a deck of cards. It is far less imposing than the IV poles used for IVIG. Most SCIg pumps are provided by the home infusion pharmacy at no additional cost to the patient and come with training on programming rates and troubleshooting alarms.

Infusion site selection and rotation is critical for comfort and absorption. The best sites have adequate subcutaneous fat and are free from scars, bruises, or areas of irritation.

Common infusion sites include:

• Abdomen — The most popular site; offers a large surface area for rotation. Stay at least two inches from the belly button.
• Upper thighs — Good alternative, especially for patients who find the abdomen sensitive.
• Upper outer arms — Useful for patients with limited abdominal tissue, though harder to access without help.
• Hips and upper buttocks — Often forgotten but excellent for rotation, particularly for patients with higher dose requirements.

A practical tip that experienced SCIg patients often share: keep a simple body diagram or journal noting where each infusion was placed. Rotating sites systematically — rather than returning to the same comfortable spot — prevents tissue hardening (lipohypertrophy) and maintains good absorption over the long term. Some patients use a clock-face pattern around the abdomen, moving one position each week.

Advantages of SCIg Over IVIG

Why are more patients switching to subcutaneous immunoglobulin? The benefits extend beyond convenience.

Fewer Systemic Side Effects

Because SCIg is absorbed gradually through subcutaneous tissue rather than entering the bloodstream all at once, the systemic side effects common with IVIG — headache, fatigue, nausea, fever, and chills — are significantly less frequent. Research published by the National Institutes of Health has consistently shown lower rates of systemic adverse events with SCIg compared to IVIG.

Steadier Immunoglobulin Levels

Weekly or biweekly SCIg dosing produces remarkably steady IgG trough levels, avoiding the peak-and-valley pattern of monthly IVIG. For many patients, this translates to feeling more consistently well — fewer “bad weeks” before the next infusion.

Greater Independence

Self-administration means no appointments to schedule, no drives to an infusion center, and no waiting for a nurse to arrive. Patients can infuse on their own timeline — evenings, weekends, even while traveling. This independence can be transformative for people who have built their lives around infusion schedules for years.

No Venous Access Required

SCIg eliminates the need for ports, PICC lines, or even peripheral IV sticks. For patients with difficult veins, a history of catheter-related infections, or anxiety about IV access, this alone can be a compelling reason to switch.

Lower Risk of Certain Serious Complications

Rare but serious IVIG-associated events — including aseptic meningitis, thromboembolic events (blood clots), and hemolytic anemia — are less commonly reported with SCIg, likely because of the slower absorption rate and lower peak serum concentrations.

Disadvantages and Limitations

SCIg is not the right choice for every patient. Honesty about the downsides is just as important as understanding the benefits.

More Frequent Infusions

Hizentra typically requires weekly infusions, compared to IVIG’s monthly schedule. While each session is shorter, some patients find that the weekly commitment feels burdensome — especially if their IVIG routine was well-established and tolerable. Hyqvia offers monthly dosing as a middle ground.

Local Site Reactions

Swelling, redness, warmth, and itching at the infusion site are common, particularly during the first few months. These reactions are almost always mild and temporary, resolving within 24–48 hours. They tend to improve over time as the body adjusts. Still, some patients find them uncomfortable or visually concerning.

Self-Administration Responsibility

Not everyone is comfortable inserting needles into their own body. Patients with significant needle phobia, dexterity limitations, or cognitive challenges may find self-infusion difficult or stressful. A caregiver can be trained to assist, but this requires another person’s consistent availability.

Not Approved for All Indications

While Hizentra is FDA-approved for both primary immunodeficiency and CIDP, Hyqvia is currently approved only for primary immunodeficiency. Patients receiving immunoglobulin for other conditions may have more limited SCIg options or may need to use SCIg off-label, which can complicate insurance coverage.

Volume Limitations

Patients requiring very high doses may find that the volume of subcutaneous infusion becomes impractical, especially with Hizentra. Multiple sites and longer infusion times may be needed for high-dose regimens.

Who Is a Good Candidate for SCIg?

SCIg may be worth discussing with a physician if any of the following apply:

• Currently receiving IVIG and experiencing bothersome systemic side effects (headache, fatigue, nausea) that don’t improve with premedication
• Experiencing the “wear-off effect” — feeling unwell in the week or two before the next IVIG infusion
• Having difficulty with IV access (collapsed veins, frequent infiltration, catheter-related infections)
• Wanting more control over scheduling and reduced dependence on nurses or infusion centers
• Traveling frequently and needing a portable treatment option
• Living in a rural area far from infusion centers
• Feeling emotionally drained by the hospital or clinic infusion experience and wanting to reclaim normalcy

SCIg may not be ideal for patients who prefer having a nurse manage the entire process, those who are not comfortable with any degree of self-care responsibility, or patients whose dose requirements make subcutaneous volumes impractical.

How to Switch from IVIG to SCIg

Switching from IVIG to SCIg is a medically straightforward process, but it requires planning and should never be done without physician supervision.

Step 1: Medical Evaluation

The prescribing physician reviews the patient’s current IVIG dose, frequency, IgG trough levels, and clinical response. If the patient is stable on IVIG, that’s typically a green light to explore SCIg.

Step 2: Dose Conversion

The total monthly IVIG dose is converted to an equivalent SCIg dose. Because subcutaneous absorption differs from intravenous, a dose adjustment factor is applied — often a 30% to 53% increase in total dose to achieve equivalent serum IgG levels. The exact conversion depends on the product and prescribing guidelines.

Step 3: Product Selection

The physician and patient decide together whether Hizentra or Hyqvia is the better fit, based on dosing frequency preference, volume tolerance, FDA-approved indication, and insurance coverage.

Step 4: Insurance Authorization

The home infusion pharmacy handles the prior authorization process for the new SCIg product. This can take one to three weeks. A seldom-discussed reality: switching products sometimes triggers a fresh round of insurance paperwork even when the underlying therapy is the same. Patients should ask the pharmacy to begin this process early to avoid a gap in treatment.

Step 5: Training

A nurse provides hands-on training in the patient’s home or at a clinic. Most patients require two to four sessions before they are comfortable infusing independently.

What the Transition Looks Like

What should patients realistically expect during the first few weeks after switching?

Week 1–2: The first self-infusion is typically nurse-supervised. Patients often feel anxious beforehand and relieved afterward. Local site reactions — small raised areas of swelling at the needle sites — are normal and expected. They usually look worse than they feel.

Week 3–4: The process starts becoming familiar. Site reactions may still occur but typically decrease in size and discomfort. Patients begin developing their own routine — a preferred time of day, a system for setting up supplies, favorite infusion sites.

Month 2–3: Most patients hit their stride. Self-infusion takes less than 15 minutes to set up, and the actual infusion runs in the background while they go about their day. IgG levels should be checked around this time to confirm the dose conversion is achieving target levels.

Month 3 and beyond: SCIg is simply part of the routine. Many patients report that their overall sense of wellbeing improves compared to IVIG, particularly if they had been experiencing wear-off effects or systemic side effects.

An underappreciated aspect of the transition: the psychological shift from being a patient who “receives” treatment to someone who “manages” their own therapy. For many people living with chronic immune conditions, this sense of agency — small as it may seem — matters enormously.

Insurance Coverage Differences

Insurance coverage for SCIg can differ significantly from IVIG coverage, and understanding the landscape before switching prevents frustrating surprises.

How SCIg is typically covered:

• Commercial insurance — Most private plans cover SCIg, but it may be classified under the pharmacy benefit rather than the medical benefit. This distinction affects co-pay structures and out-of-pocket maximums. Some patients find SCIg cheaper under the pharmacy benefit; others find the opposite.
• Medicare — Medicare Part B covers IVIG for patients with primary immunodeficiency, including an administration fee for home infusion. SCIg coverage under Medicare has historically been more complicated. As of recent policy updates, Medicare covers SCIg drugs under Part B and associated services under Part B’s home infusion therapy benefit. However, coverage nuances change frequently — verify current details with a pharmacy benefits specialist.
• Medicaid — Coverage varies by state. Some state Medicaid programs cover SCIg readily; others may require additional documentation or prefer IVIG.

A cost detail that catches patients off guard: even when the drug itself is covered, the ancillary supplies (pump rental, tubing, needles) may be billed separately. Reputable home infusion pharmacies include these supplies in their dispensing package, but patients should confirm this in writing before starting therapy.

Both Hizentra and Hyqvia manufacturers offer patient assistance programs for eligible patients who face significant co-pays. The home infusion pharmacy should proactively investigate these programs during the insurance verification process.

Your Next Steps

If subcutaneous immunoglobulin sounds like it might be right for you, here are specific actions to take:

1. Bring it up with your immunologist or neurologist. If your physician hasn’t mentioned SCIg, ask directly: “Am I a candidate for switching to subcutaneous immunoglobulin?” Come prepared with your reasons — side effects you’re experiencing, scheduling difficulties, or the wear-off effect.
2. Request a cost comparison. Ask the home infusion pharmacy to investigate coverage for both Hizentra and Hyqvia under your insurance plan before choosing a product.
3. Talk to another patient. Disease-specific organizations like the American Academy of Allergy, Asthma & Immunology and the GBS|CIDP Foundation International can connect you with patients who have made the switch. Hearing firsthand experience helps more than any article can.
4. Watch, but verify. Manufacturer websites and YouTube feature SCIg self-infusion demonstrations. These can reduce anxiety by showing exactly what the process looks like. However, always follow the training provided by your own healthcare team, as techniques vary by product and individual dose.
5. Plan the timing. Don’t rush the switch. Coordinate with your physician and pharmacy so that your last IVIG infusion and first SCIg dose overlap appropriately, and training is completed before you are expected to infuse independently.

Switching to SCIg is not a small decision, but for many patients, it marks the moment when immunoglobulin therapy stops being something that disrupts their life and starts being something they barely think about. The needles are small. The pump is quiet. And the freedom — to infuse when and where it suits you — is real.